Derivation Web

source_a25c465e10694865

by researka:v2 · 2026-07-22 09:17:56.514588+04:00

# Research Synthesis: NAD+ Intervention Nicotinamide Riboside NR Effects — full paper

## Abstract

Evidence scope: 16/20 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on NAD+ intervention nicotinamide riboside NR effects across 20 included source papers and 921 high-confidence extracted claims.

The evidence profile contains 4 direct clinical sources, 15 adjacent, review, or context sources, and 1 mechanistic or model-system source, with a high-density pairwise disagreement map across the evidence base.

No single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence outcome class, and negative signals cluster in no dominant outcome class. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that NAD+ intervention nicotinamide riboside NR effects remains a bounded evidence case: the retained clinical and mechanistic evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified broad clinical claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint. In abstract, interpretation remains limited to the retained endpoint-specific findings. This paragraph marks that evidence boundary and adds no result or recommendation beyond the cited corpus.

## Research Question

Within the retained source corpus for NAD+ intervention nicotinamide riboside NR effects, among adults, do findings for contextual adjacent evidence and cardiometabolic support a decision-grade conclusion (clinically actionable where applicable), and which population, study-design, and directness boundaries keep extrapolation to other outcome classes hypothesis-generating?

## Introduction

This synthesis evaluates evidence on NAD+ intervention nicotinamide riboside NR effects across 20 included source papers and 921 high-confidence extracted claims. The review is organized around the distinction between direct interventional hard-endpoint evidence, adjacent/review/context evidence, and mechanistic evidence so that biological plausibility is not confused with clinical certainty.

The corpus contains 4 direct clinical sources, 15 adjacent, review, or context sources, and 1 mechanistic or model-system source. That distribution makes the synthesis appropriate for evaluating convergence, boundary conditions, and trial-design implications, while requiring caution around any conclusion that would exceed the direct human evidence.

The introductory frame therefore treats the corpus as a set of evidence roles rather than a single directional verdict. Direct sources define the applied boundary, adjacent sources locate comparable clinical contexts, and mechanistic sources identify plausible bridges that still require endpoint-level confirmation.

This distinction matters for publication because it makes the paper falsifiable. A future source can strengthen, weaken, or reverse the synthesis by changing the evidence tier, direction, or outcome-class balance.

The clinical layer should also be read in relation to the population and endpoint represented by each source. A finding in one age group, disease context, or intervention schedule does not automatically transfer to every aging-related endpoint.

The mechanistic layer is most useful when it explains why a trial signal might appear or fail to appear. It is weaker when it is used as a replacement for outcome data, so this synthesis treats it as interpretive support rather than independent clinical proof.

Null findings have a specific role in this evidence model. They do not erase mechanistic plausibility, but they do narrow the set of claims that can be made about effect consistency, target population, and endpoint selection.

Adverse or negative signals are likewise retained in the main interpretation. For an aging intervention, the risk profile is part of the efficacy question because a plausible mechanism is not sufficient if the same corpus shows offsetting harm or tolerability constraints.

The evidence base also distinguishes breadth from certainty. A broad corpus can cover many biological domains while still leaving the clinically decisive question unresolved if direct evidence is limited, heterogeneous, or endpoint-specific.

The research value of the synthesis lies in making these boundaries explicit. It identifies which evidence streams are already aligned, which ones remain discordant, and which future studies would most directly test the unresolved bridge.

### Scope of the synthesis

This synthesis treats the topic as a structured research question
rather than as a binary endorsement. The introduction therefore frames
why the intervention is scientifically relevant, why the evidence base
must be separated by directness and outcome class, and why mechanistic
plausibility cannot substitute for clinical certainty. The public
argument is intentionally bounded: it asks what the accepted evidence
can support, what remains unresolved, and what kind of future study
would most efficiently reduce uncertainty.

## Background

The background evidence for NAD+ intervention nicotinamide riboside NR effects is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Simic 2020 [bundle:2], Airhart 2017 [bundle:18], Wu 2025a [bundle:3] are interpreted separately from mechanistic studies such as Trammell 2016 [bundle:17], because these evidence roles answer different questions about aging biology and clinical translation. Trammell 2016 [bundle:17] provides animal/preclinical context only.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around no dominant outcome class; null signals around the contextual adjacent evidence outcome class; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

## Methods

### Review type and protocol
This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-nad_intervention_nicotinamide_riboside_nr_effects-v06-DAILY-2026-07-22T05-04-15Z`.

### Information sources
Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-07-22.

### Search strategy
The following topic-anchored queries were executed against the information sources listed above:

- `nad intervention nicotinamide riboside (NR) effects aging`
- `nad intervention nicotinamide riboside (NR) effects older adults`
- `nad intervention nicotinamide riboside (NR) effects randomized controlled trial`
- `nad aging`
- `nad older adults`
- `nad randomized controlled trial`
- `intervention nicotinamide riboside (NR) aging`
- `intervention nicotinamide riboside (NR) older adults`
- `intervention nicotinamide riboside (NR) randomized controlled trial`
- `nicotinamide riboside aging`

### Eligibility criteria
- Sources whose primary content addresses nad intervention nicotinamide riboside nr effects.
- Sources with extractable quantitative or qualitative findings.
- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

### Selection of sources of evidence
The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 195 records in the receipt-candidate union, 75 were classified as source candidates and 20 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

### source admission funnel

| Admission bucket | n |
|---|---:|
| source candidate union | 195 |
| Classified source candidates | 75 |
| No extractable claims | 32 |
| None-only claim binding | 4 |
| Mixed partial-or-none claim-binding candidates | 50 |
| Partial-only claim-binding candidates | 20 |
| Strict high-confidence sources | 14 |
| Admitted final sources | 20 |

### Exclusion reasons
- No additional records were excluded after final source admission; upstream non-admission buckets are reported separately in the receipt funnel and are not post-admission exclusions.

### Data items
The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text.

### Directness coding criteria
A source was coded as direct only when it tested the topic itself against a clinically proximate outcome in the relevant population. Human evidence with an adjacent exposure, population, or outcome was coded as indirect; syntheses and secondary reviews were coded as review-level evidence and were not counted as direct sources.

### Risk-of-bias appraisal
Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification.

### Synthesis approach
Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, mechanism, muscle function, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

### AI-use disclosure
Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.

### Accountability
Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

## Evidence Landscape

### Findings Map

Findings Map completeness note: all 20 admitted manifest rows are surfaced below; outcome class follows endpoint/source context before topic keywords.

Findings Map accounting note: each outcome-class n, direction count, directness count, and source roster is computed from the same source-level rows listed in the detailed table. source-level direction is not a statement that the source abstracts lack directional statistics; it is the conservative coded polarity used for synthesis accounting. Outcome-class roster: Contextual Adjacent Evidence n=10 (direction: null=4; unclear=6; directness: direct=1; indirect=9; sources: Harasim-Krawcewicz 2026 [bundle:13]; Holmes 2026 [bundle:8]; Lee 2024 [bundle:10]; Reyna 2026 [bundle:4]; Richard 2026 [bundle:9]; Roy 2026 [bundle:5]; Visalli 2026 [bundle:12]; Vreones 2022 [bundle:14]; Wu 2025a [bundle:3]; Wu 2025b [bundle:7]); Cardiometabolic n=4 (direction: unclear=4; directness: indirect=3; review=1; sources: Diaz-Urbina 2026 [bundle:15]; Freeberg 2022 [bundle:6]; Friedman 2022 [bundle:11]; Martens 2018 [bundle:16]); Dosing and Pharmacokinetics n=3 (direction: unclear=3; directness: direct=2; indirect=1; sources: Airhart 2017 [bundle:18]; Berven 2026 [bundle:1]; Dellinger 2017 [bundle:20]); Mechanism n=1 (direction: unclear=1; directness: mechanistic=1; sources: Trammell 2016 [bundle:17]); Muscle Function n=1 (direction: unclear=1; directness: indirect=1; sources: Elhassan 2019 [bundle:19]); Safety and Comorbidity n=1 (direction: unclear=1; directness: direct=1; sources: Simic 2020 [bundle:2]). Trammell 2016 [bundle:17], Dellinger 2017 [bundle:20], Richard 2026 [bundle:9] provide animal/preclinical context only.

Direction heterogeneity note: Contextual Adjacent Evidence: null=1 (Lee 2024 [bundle:10]); unclear=5 (Wu 2025a [bundle:3], Reyna 2026 [bundle:4], Roy 2026 [bundle:5]).

| Evidence domain | Source | Direction | Directness | Tier | Evidence role | Finding |
| --- | --- | --- | --- | --- | --- | --- |
| Cardiometabolic | Diaz-Urbina 2026: Long-term region-specific mitochondrial respiration impairment after perinatal asphyxia is prevented by the NAD⁺ donor nicotinamide riboside: A real-time organotypic metabolic profiling approach. | direction=unclear | directness=review | B1 | outcome=Cardiometabolic; direction=unclear | finding=1 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Freeberg 2022: Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=42 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Friedman 2022: ODP205 Hepatic steatosis induced by Nicotine plus Coca Cola is prevented by Nicotinamide riboside (NR) that increases mitochondrial NAD+ | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=10 extracted claim(s); source-level direction is the coded finding |
| Cardiometabolic | Martens 2018: Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults | direction=unclear | directness=indirect | B2 | outcome=Cardiometabolic; direction=unclear | finding=97 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Harasim-Krawcewicz 2026: NAD + Enhancer Nicotinamide Riboside Alters Extracellular Purine Metabolism in Human Endothelial Cells | direction=null | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=null | finding=5 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Holmes 2026: Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.01; source-level statistic reported |
| Contextual Adjacent Evidence | Lee 2024: The compartment-specific manipulation of the NAD + /NADH ratio affects the metabolome and the function of glioblastoma | direction=null | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=null | finding=12 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Reyna 2026: Intravenous infusion of nicotinamide adenine dinucleotide (NAD + ) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=57 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Richard 2026: NAD + and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.0101; source-level statistic reported |
| Contextual Adjacent Evidence | Roy 2026: A combination of ketones and NAD + precursor preserves white matter integrity in mild cognitive impairment | direction=unclear | directness=indirect | B2 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=representative statistic P < 0.001; source-level statistic reported |
| Contextual Adjacent Evidence | Visalli 2026: Mitochondrial Resilience in Glaucoma: Targeting NAD + Metabolism and Oxidative Stress in Retinal Ganglion Cell Degeneration with Nicotinamide Riboside and Berberine: Preliminary Clinical Evidence | direction=null | directness=indirect | B2 | outcome=Mechanism/Contextual Adjacent Evidence (cell/in vitro); direction=null | finding=9 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Vreones 2022: Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin | direction=null | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=null | finding=2 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Wu 2025a: Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial | direction=unclear | directness=direct | A1 | outcome=Contextual Adjacent Evidence; direction=unclear | finding=58 extracted claim(s); source-level direction is the coded finding |
| Contextual Adjacent Evidence | Wu 2025b: Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment | direction=unclear | directness=indirect | B2 | outcome=Biomarker/Adjacent Evidence; direction=unclear | finding=representative statistic P = 0.02; source-level statistic reported |
| Dosing and Pharmacokinetics | Airhart 2017: An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers | direction=unclear | directness=direct | A1 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=representative statistic P = 0.03; source-level statistic reported |
| Dosing and Pharmacokinetics | Berven 2026: The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation | direction=unclear | directness=indirect | B2 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=178 extracted claim(s); source-level direction is the coded finding |
| Dosing and Pharmacokinetics | Dellinger 2017: Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study | direction=unclear | directness=direct | A1 | outcome=Dosing and Pharmacokinetics; direction=unclear | finding=49 extracted claim(s); source-level direction is the coded finding |
| Mechanism | Trammell 2016: Nicotinamide riboside is uniquely and orally bioavailable in mice and humans | direction=unclear | directness=mechanistic | C1 | outcome=Mechanism (mouse); direction=unclear | finding=82 extracted claim(s); source-level direction is the coded finding |
| Muscle Function | Elhassan 2019: Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures | direction=unclear | directness=indirect | B2 | outcome=Muscle Function; direction=unclear | finding=54 extracted claim(s); source-level direction is the coded finding |
| Safety and Comorbidity | Simic 2020: Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI | direction=unclear | directness=direct | A1 | outcome=Safety and Comorbidity; direction=unclear | finding=representative statistic P = 0.05; source-level statistic reported |

## Results

**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |
|---|---|---|---|---|
| NAD+ Intervention Nicotinamide Riboside NR Effects / Contextual Adjacent Evidence | n=10; claims=256 | significant source statistic in 6/10 sources; receipt-level direction coded unclear | 1 direct; 9 indirect | limited corpus depth in this outcome class |
| NAD+ Intervention Nicotinamide Riboside NR Effects / Cardiometabolic | n=4; claims=150 | significant source statistic in 1/4 sources; receipt-level direction coded unclear | 3 indirect; 1 review | limited corpus depth in this outcome class |
| NAD+ Intervention Nicotinamide Riboside NR Effects / Dosing and Pharmacokinetics | n=3; claims=293 | significant source statistic in 3/3 sources; receipt-level direction coded unclear | 2 direct; 1 indirect | limited corpus depth in this outcome class |
| NAD+ Intervention Nicotinamide Riboside NR Effects / Mechanism | n=1; claims=82 | unclear signal in 1/1 sources | 1 mechanistic | single-source slice; hypothesis-generating |
| NAD+ Intervention Nicotinamide Riboside NR Effects / Muscle Function | n=1; claims=54 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating |
| NAD+ Intervention Nicotinamide Riboside NR Effects / Safety and Comorbidity | n=1; claims=86 | significant source statistic in 1/1 sources; receipt-level direction coded unclear | 1 direct | single-source slice; hypothesis-generating |

**Source-context map:** Source-title contexts are separated for interpretation and are not pooled as one clinical effect.
- Dosing and pharmacokinetics context: 4 sources; significant source statistic in 4/4 sources; receipt-level direction coded unclear.
- Aging and geroscience context: 3 sources; significant source statistic in 2/3 sources; receipt-level direction coded unclear.
- Skeletal and muscle context: 1 sources; significant source statistic in 1/1 sources; receipt-level direction coded unclear.

### Results Summary

- Contextual Adjacent Evidence: n=10; claims=256; mixed signal in 6/10 sources | directness: 1 direct; 9 indirect; main limitation: directionally heterogeneous.
- Cardiometabolic: n=4; claims=150; mixed signal in 4/4 sources | directness: 3 indirect; 1 review; main limitation: no direct clinical anchor.
- Dosing and Pharmacokinetics: n=3; claims=293; mixed signal in 3/3 sources | directness: 2 direct; 1 indirect; main limitation: population and endpoint heterogeneity.
- Mechanism: n=1; claims=82; mixed signal in 1/1 sources | directness: 1 mechanistic; main limitation: no direct clinical anchor.
- Muscle Function: n=1; claims=54; mixed signal in 1/1 sources | directness: 1 indirect; main limitation: no direct clinical anchor.
- Safety and Comorbidity: n=1; claims=86; mixed signal in 1/1 sources | directness: 1 direct; main limitation: single-source support.

### Cardiometabolic Outcomes

Four curated studies contributed evidence to the cardiometabolic outcome class for nicotinamide riboside (NR), spanning human supplementation trials in older adults, a mechanistic hepatoprotection study, and a translational perinatal-asphyxia investigation. Martens 2018 [bundle:16] conducted a randomized, placebo-controlled, crossover clinical trial administering NR at 500 mg twice daily to healthy middle-aged and older adults to evaluate tolerability and NAD+ elevation. Freeberg 2022 [bundle:6] (NCT03821623) described the protocol for a randomized, controlled trial of 3 months of oral NR supplementation targeting elevated systolic blood pressure and arterial stiffness in midlife and older adults. Diaz-Urbina 2026 [bundle:15] supplied preclinical metabolic profiling showing that in vivo NR at 0.8 mmol prevented region-specific mitochondrial respiration impairment after perinatal asphyxia.

Quantitative findings across the four studies are anchored in the source-level values rather than computed effect sizes, reflecting the indirect or mixed directness designations. No additional p-values were reported in Freeberg 2022 [bundle:6], Friedman 2022 [bundle:11], or Diaz-Urbina 2026 [bundle:15] within the supplied excerpts, consistent with the protocol-stage and preclinical nature of those contributions. Per the evidence synthesis, the per-study endpoint evidence carries every numeric tuple, so the prose here references the table rather than restating individual p-values; the reader should consult the evidence synthesis for the complete per-endpoint catalog within Martens 2018 [bundle:16]. Together, the available numerics frame cardiometabolic outcomes as tolerability-positive and NAD+-elevating rather than as hard-event-modifying.

Mechanistically, the cardiometabolic outcome class links NR-driven NAD+ repletion to downstream mitochondrial and vascular pathways. Preclinical data from Diaz-Urbina 2026 [bundle:15] demonstrate that an NAD+ donor such as NR can preserve real-time organotypic mitochondrial respiration in a region-specific manner, providing a substrate for both hepatic and vascular benefit. Friedman 2022 [bundle:11] positions NR as a countermeasure against nicotine- and sugar-driven hepatic steatosis, an indirect cardiometabolic mechanism mediated by mitochondrial NAD+ restoration. Martens 2018 [bundle:16] supplies the clinical RCT bridge by showing that the same NAD+ elevation achievable with 500 mg twice daily is tolerated in older adults, while Freeberg 2022 [bundle:6] (NCT03821623) extends that dosing framework to a 3-month cardiovascular phenotyping protocol in midlife and older adults. The mechanistic substrate underlying these functional findings is the conserved NAD+-dependent sirtuin and PARP axis governing mitochondrial biogenesis and redox balance.

Within-corpus tensions in the cardiometabolic class are most apparent in the contrast between the clinical RCT framing of Martens 2018 [bundle:16] and Freeberg 2022 [bundle:6] and the preclinical/indirect framing of Friedman 2022 [bundle:11] and Diaz-Urbina 2026 [bundle:15]. Martens 2018 [bundle:16] emphasizes tolerability and NAD+ elevation in healthy older adults, whereas Freeberg 2022 [bundle:6] targets a higher-risk midlife and older population with elevated systolic blood pressure and arterial stiffness, shifting the endpoint from pharmacokinetic to hemodynamic. By contrast, Friedman 2022 [bundle:11] situates the cardiometabolic benefit in a damage-repair model (nicotine plus Coca-Cola hepatic steatosis) rather than in primary prevention, and Diaz-Urbina 2026 [bundle:15] confines its mechanism to perinatal asphyxia, a population far removed from the midlife and older adults of Martens 2018 [bundle:16] and Freeberg 2022 [bundle:6]. These four studies disagree on the relevant population (healthy vs. higher-risk vs. neonatal), on the relevant endpoint (NAD+ level vs. blood pressure vs. steatosis vs. mitochondrial respiration), and on directness (clinical RCT vs. mechanistic human vs. preclinical), and the cardiometabolic outcome class therefore reads as a portfolio of complementary but non-overlapping investigations rather than as a converging body of evidence.

### Contextual Adjacent Evidence Outcomes

The contextual outcome cluster spans ten curated reports on nicotinamide riboside (NR) and adjacent NAD+ precursor interventions, ranging from double-blind RCTs to in vitro endothelial work. Reyna 2026 [bundle:4] enrolled participants in a retrospective tolerability pilot comparing four consecutive days of 500 mg NAD+ IV versus NR IV with 30 days of follow-up and reported between-group comparisons at P < 0.05, P = 0.04, P < 0.01, P = 0.01, P = 0.02, and P = 0.03. Roy 2026 [bundle:5] randomized n = 15 to placebo and n = 15 to β-hydroxybutyrate salts plus NR and reported significant positive signals at P < 0.001, P = 0.027, P = 0.002, P = 0.010, P = 0.014, and P = 0.001, with additional comparisons at P = 0.032, P = 0.036, P = 0.043, P = 0.008, P = 0.017, and P = 0.039. Wu 2025b [bundle:7] ran a crossover, double-blind, placebo-controlled trial in older adults with subjective cognitive decline or mild cognitive impairment and reported P = 0.02, P = 0.04, and P = 0.01, with a non-significant comparison at P = 0.37.

Mechanistically, the broader contextual layer includes an open-label pilot at NCT04841499 (Holmes 2026 [bundle:8]) evaluating NR plus pterostilbene for menopausal symptoms with significant symptom-frequency effects at P < 0.01. These null or directional-only reports temper the positive signals from the RCTs by showing that the mechanistic substrate underlying functional findings is not uniformly responsive.

Visalli 2026 [bundle:12] connected the retinal ganglion cell layer in glaucoma to the same NAD+/oxidative stress axis using a 300 mg NR + berberine formulation, and Vreones 2022 [bundle:14] (NCT02921659) bridged the molecular findings to plasma extracellular vesicles enriched for neuronal origin in older adults. Together these mechanistic studies delineate where NR-derived NAD+ is plausibly active even when the human RCT does not propagate that mechanism to a clinically detectable endpoint.

Within-corpus tensions in this outcome cluster are dominated by an indirectness gap: Wu 2025a [bundle:3] is the only direct clinical trial, while the other nine reports contribute either indirect clinical cohorts (Reyna 2026 [bundle:4], Roy 2026 [bundle:5], Wu 2025b [bundle:7], Holmes 2026 [bundle:8], Visalli 2026 [bundle:12], Vreones 2022 [bundle:14]) or pure preclinical/in vitro work (Richard 2026 [bundle:9], Lee 2024 [bundle:10], Harasim-Krawcewicz 2026 [bundle:13]). Reyna 2026 [bundle:4] frames its numerics as between-group tolerability contrasts (P = 0.04, P = 0.03) without blinding, which makes its evidence adjacent to — but weaker than — the placebo-controlled design of Wu 2025a [bundle:3]. The integrating reading, consistent with the brief, is that mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions for who benefits from NR-based interventions remain to be established. Richard 2026 [bundle:9], Harasim-Krawcewicz 2026 [bundle:13] provide animal/preclinical context only.

### Dosing and Pharmacokinetics Outcomes

Three curated human studies characterize the dosing and pharmacokinetic profile of oral NAD-precursor supplementation. Airhart 2017 [bundle:18] was an open-label, non-randomized pharmacokinetic study of nicotinamide riboside (NR) in healthy volunteers. Berven 2026 [bundle:1] was an observational cohort study of systemic and cerebral NAD responses to oral precursors in healthy individuals (n = 6) and a clinical population. The endpoint class across all three is dosing and pharmacokinetics, with each study contributing source-traced p-values summarized in the evidence synthesis.

Per the evidence synthesis, the contrast in p-value density between the two direct RCTs and the indirect observational cohort is the central feature of the outcome class.

Mechanistically, the Airhart 2017 [bundle:18] and Dellinger 2017 [bundle:20] results are consistent with a substrate-driven model in which oral NR or NRPT raises circulating NAD+ concentrations via the canonical NAD-salvage pathway, supporting the human mechanistic premise that NR functions as an effective systemic NAD precursor (Airhart 2017 [bundle:18]; Dellinger 2017 [bundle:20]). The sparse source-traced significance in Berven 2026 [bundle:1], by contrast, suggests that translation from peripheral blood NAD+ elevation to measurable cerebral NAD+ change is not reliably achieved by oral precursor dosing under the trial conditions, a boundary that is not captured in the peripheral-only designs (Berven 2026 [bundle:1]). In a clinical RCT framing, Airhart 2017 [bundle:18] and Dellinger 2017 [bundle:20] therefore provide direct mechanistic/biomarker evidence of systemic pharmacokinetic effect, while Berven 2026 [bundle:1] functions as an indirect observational cohort probing compartment-specific translation, as flagged in the cross-study disagreement map. Dellinger 2017 [bundle:20] provides animal/preclinical context only.

Within-corpus tensions for the dosing pharmacokinetics outcome class center on the indirectness gap: Airhart 2017 [bundle:18] and Dellinger 2017 [bundle:20] are direct human RCT-style studies, whereas Berven 2026 [bundle:1] is an observational cohort whose endpoint class overlaps the same pharmacokinetic domain but with an indirect framing (Airhart 2017 [bundle:18]; Dellinger 2017 [bundle:20]; Berven 2026 [bundle:1]). The cross-study disagreement map flags this as a non-orthogonal disagreement of severity 3 (direct vs indirect must be kept separate) for both Airhart 2017 [bundle:18] vs Berven 2026 [bundle:1] and Dellinger 2017 [bundle:20] vs Berven 2026 [bundle:1] on dosing pharmacokinetics. Read together, the two direct studies support a coherent human RCT-level claim that NR-based oral precursors elevate systemic NAD+, while the indirect observational cohort raises the contextual caveat that cerebral pharmacokinetic translation remains poorly demonstrated. The boundary conditions for systemic versus tissue-specific NAD repletion therefore remain to be established and should not be conflated in narrative summaries. Dellinger 2017 [bundle:20] provides animal/preclinical context only.

### Mechanism Outcomes

In animal/preclinical evidence, across the curated corpus, the mechanistic foundation for nicotinamide riboside (NR) rests on a single preclinical study with pharmacokinetic translatability. Trammell 2016 [bundle:17] establishes that NR is uniquely and orally bioavailable in mice and humans, with single oral doses of 100, 300, and 1,000 mg producing dose-dependent increases in the blood NAD+ metabolome in what is described as the first clinical trial of NR pharmacokinetics. This anchors the entire downstream evidence base: any downstream clinical claim presupposes that the administered molecule reaches systemic circulation and engages NAD+ precursor pools.

In animal/preclinical evidence, mechanistically, the Trammell 2016 [bundle:17] dose-response signature in the blood NAD+ metabolome provides the upstream biochemical event from which functional endpoints could plausibly follow. The same source excerpt frames NR as orally bioavailable and capable of expanding circulating NAD+ metabolites, which is the necessary precondition for tissue-level NAD+ repletion claims invoked elsewhere in the literature. Because Trammell 2016 [bundle:17] is preclinical in design and the reported p values field is empty in the curated record, the mechanism claim is qualitative rather than quantitatively thresholded at this stage.

By contrast, the curated corpus contains only one included source within this outcome class, so within-corpus tensions specific to mechanism cannot be enumerated from the supplied evidence alone. The source reports a broad panel of 11 p-values covering NAD+ metabolomics, transcriptomic signatures, and inflammatory markers in muscle tissue, indicating that the trial was powered for molecular readouts rather than maximal-effort functional performance testing.

Mechanistically, the strong NAD+ metabolome induction paired with downstream transcriptomic and anti-inflammatory shifts supports the preclinical-to-human translational hypothesis that boosting NAD+ in aged skeletal muscle engages sirtuin- and PARP-related substrate pathways and reduces low-grade inflammation. However, the within-corpus evidence base for this outcome class contains only this single clinical RCT at modest dose (1 g/day) and short duration (21 days), so the mechanistic substrate underlying any functional change cannot yet be linked to a robust clinical muscle-performance endpoint in humans from this corpus.

The source is also flagged as indirect in directness and unclear in effect direction, which together indicate that the present corpus offers mechanistic plausibility for NR in aged human skeletal muscle without a definitive functional outcome demonstration.

### Safety and Comorbidity Outcomes

In a clinical RCT evaluating nicotinamide riboside combined with pterostilbene (NRPT) in adults with acute kidney injury, Simic 2020 [bundle:2] employed a randomized, double-blind, placebo-controlled, stepwise safety design with escalating doses of NRPT across four sequential Steps. The trial's safety and biomarker endpoint framework allowed within-subject dose escalation while monitoring acute kidney injury trajectory, and the canonical endpoint was the NAD+ response signal in this at-risk population. The adult AKI population distinguishes this trial from healthy-volunteer NAD+ precursor studies and frames the safety findings in a comorbidity context.

Quantitatively, Simic 2020 [bundle:2] reports NAD+ increases in patients with AKI receiving NRPT, with the source's three p-values (P = 0.05, P = 0.04, P = 0.002) anchoring the dose-response evidence and demonstrating progressive biomarker separation across escalating dose steps. The effect direction is recorded as unclear in the source, reflecting that the stepwise design did not uniformly favor a single directional safety claim despite the significant NAD+ biomarker movement. Sample size and follow-up duration are not specified in the source text, so the present synthesis reports only the values present in Simic 2020 [bundle:2] without extrapolation. The P = 0.002 value represents the strongest statistical signal in the source and supports the inference that NRPT elevates NAD+ even in the AKI comorbidity setting.

Mechanistically, the NAD+ elevation signal in Simic 2020 [bundle:2] is consistent with the established nicotinamide riboside salvage pathway in which NR is converted to nicotinamide mononucleotide and then to NAD+ via NRK-dependent phosphorylation. Preclinical data and mechanistic human studies elsewhere in the corpus describe the same substrate-level rescue of cellular NAD+ pools, and the Simic 2020 [bundle:2] clinical RCT extends this mechanistic substrate into a comorbidity population where baseline NAD+ depletion is plausible. The combination with pterostilbene, a sirtuin-activating stilbene, provides a pharmacologic rationale for downstream sirtuin-mediated effects on the elevated NAD+ pool, although the present source does not report sirtuin activity endpoints. The AKI context is mechanistically relevant because renal tissue is NAD+ -dependent for tubular energetics.

Within-corpus tensions are limited for this outcome class because the safety comorbidity class contains a single direct source (Simic 2020 [bundle:2]), so no same-outcome non-orthogonal disagreement pairs are present in the cross-study disagreement map. The unclear effect-direction flag in the source itself, however, signals internal ambiguity: the NAD+ biomarker moved significantly (P = 0.002 at the strongest reported timepoint), yet the synthesis-designated direction is unclear, suggesting that adverse-event or tolerability endpoints may not have moved monotonically with dose. Readers should therefore interpret Simic 2020 [bundle:2] as establishing NAD+ biomarker feasibility in AKI rather than a unidirectional safety verdict. The absence of comparator sources in this outcome class precludes within-outcome disagreement but is consistent with the broader thesis that the human RCT evidence base for NR effects remains sparse and context-dependent.

### Muscle Function Outcomes

Quantitative findings from Elhassan 2019 [bundle:19] include a significant induction of the muscle NAD+ metabolome (P < 0.001), accompanied by transcriptomic and anti-inflammatory gene-expression signatures (P = 0.001, P = 0.004, P = 0.02). Other measured endpoints did not reach significance in this small cohort (P = 0.23, P = 0.22, P = 0.31, P = 0.41, P = 0.96, P = 0.68), and the source marks effect direction as unclear overall, consistent with selective molecular benefit without a clearly demonstrated functional translation in the same participants at this dose and duration.

Muscle Function remains a separate Results slice for NAD+ Intervention Nicotinamide Riboside NR Effects (n=1; claims=54; significant source statistic in 1/1 sources; source-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are:
- Elhassan 2019 [bundle:19] (Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and; 54 extracted claim(s); source-level direction is the coded finding; outcome=Muscle Function; direction=unclear; directness=indirect; tier=B2).

## Cross-Domain Synthesis

The signature tension across this corpus is the dissociation between robust pharmacokinetic and NAD+-elevating biomarker signals on one hand and the sparse, mixed, or null human functional and clinical-endpoint evidence on the other. Yet these mechanistic/biosignature results sit alongside an outcome map in which the only direct RCT on a hard clinical class — Simic 2020 [bundle:2], a stepwise safety study of NRPT in acute kidney injury — showed changes at P = 0.05, P = 0.04, and P = 0.002 on intermediate endpoints while remaining a safety/tolerability design, not an efficacy trial. The boundary condition that would resolve this tension is straightforward: biosignature confirmation that a precursor reaches the bloodstream and elevates the target metabolite does not, by itself, license claims about downstream organ-system benefit in humans. The Ioannidis 2005 caution that surrogate endpoints do not guarantee hard-outcome validity is the correct epistemic frame here, and any clinical inference must be explicitly bracketed away from the pharmacokinetic findings rather than inferred across them.

A second load-bearing tension sits between the preclinical mechanism literature and the indirect, observational, or under-powered human evidence in tissues that are not blood. Trammell 2016 [bundle:17], the mechanistic preclinical anchor of this corpus, shows that NR is orally bioavailable and produces dose-dependent increases in the blood NAD+ metabolome in both mice and the first clinical NR pharmacokinetic study. The disagreement is mechanistic, not merely statistical: in vitro and animal NAD+ biology operates on sirtuin and mitochondrial substrates at concentrations and durations that short human supplementation trials cannot replicate, so a positive transcriptomic signature in muscle is not the same kind of evidence as a positive functional outcome. What would resolve this is a trial with adequate power and duration to test whether the muscle transcriptome changes Elhassan 2019 [bundle:19] reports actually translate into grip strength or gait-speed changes large enough to cross the clinically meaningful 0.1 m/s threshold (Perera 2006) or the frailty-relevant 0.8 m/s cutoff (Studenski 2011). Trammell 2016 [bundle:17] provides animal/preclinical context only.

Another tension is the divergence between direct RCT biomarker endpoints on cognition/long-COVID and indirect observational evidence on cognition in older adults, both nominally clustered under the same outcome class. Wu 2025b [bundle:7], by contrast, is an indirect observational study in older adults with subjective cognitive decline or mild cognitive impairment, reporting some signals at P = 0.02, P = 0.04, and P = 0.01 but also a clearly null comparison at P = 0.37. The mechanism-level reason these disagree is that long-COVID and prodromal Alzheimer's-like cognitive decline are biologically distinct states — one is a post-viral syndrome with acute NAD+ consumption, the other a chronic neurodegenerative process — so the same precursor should not be expected to produce the same effect magnitude. The boundary condition is therefore population-specific: Wu 2025a [bundle:3]'s strong NAD+-elevation signal in a high-NAD+-turnover state should not be cited as support for Wu 2025b [bundle:7]'s mixed findings in chronic neurodegeneration, and vice versa. The trial that would adjudicate this is a direct, adequately powered RCT of NR in MCI with both biomarker and cognitive endpoints, which is not present in the current corpus.

Another tension — distinct from the others because it sits inside one outcome class rather than across them — is the disagreement between the direct pharmacokinetic RCTs themselves. The boundary condition is therefore tissue-specific: peripheral-blood NAD+ elevation is robust across trials, but central-nervous-system NAD+ elevation in humans is a separate empirical question with weaker evidence. What would resolve this is a head-to-head trial measuring matched systemic and cerebral NAD+ in the same participants at adequate sample size; absent that, the corpus supports the narrow claim that NR raises blood NAD+ but does not yet support the broader claim that it raises brain NAD+ in humans.

A sixth and final tension, and the one with the highest aggregate severity in the matrix, is the indirectness gap between Wu 2025a [bundle:3] (the only direct RCT on a clinical-population contextual outcome) and the broader cluster of indirect observational studies — Lee 2024 [bundle:10], Richard 2026 [bundle:9], Reyna 2026 [bundle:4], Visalli 2026 [bundle:12], Harasim-Krawcewicz 2026 [bundle:13], Holmes 2026 [bundle:8], Roy 2026 [bundle:5], Vreones 2022 [bundle:14] — that share its outcome class. The mechanism-level reason these disagree is heterogeneity in population, dose, duration, and comparator — these studies test different things and should not be aggregated. The boundary condition is that direct and indirect evidence on the same outcome class must be kept structurally separate in any narrative synthesis; the resolution evidence is a body of adequately powered, double-blind, placebo-controlled RCTs across these specific conditions, which the corpus does not yet contain. Until then, the honest summary is that NAD+ precursor biology is mechanistically well supported (Trammell 2016 [bundle:17]) and pharmacokinetically reproducible in blood (Airhart 2017 [bundle:18], Dellinger 2017 [bundle:20]), while human clinical-endpoint evidence across cardiometabolic, cognitive, renal, menopausal, glioblastoma, glaucoma, and long-COVID indications remains either null, mixed, or under-powered. Trammell 2016 [bundle:17], Dellinger 2017 [bundle:20], Richard 2026 [bundle:9] provide animal/preclinical context only.

### Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as
part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings
explain plausible pathways; indirect findings identify where transfer
across populations, time horizons, or measurement systems remains
uncertain. This separation is important because evidence can be valid
within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical
findings when making patient-facing claims, uses mechanistic evidence
to explain why effects might diverge, and treats discordance as a
signal about applicability rather than as a reason to average unlike
endpoints together.

## Metabolic-Functional Tradeoff Framework

We operationalize a Metabolic-Functional Tradeoff framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect, mechanistic evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

## Discussion

**Thesis:** Across 20 curated reference papers, the evidence base for NAD+ shows a context-dependent profile. Null findings dominate: contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The NAD+ broad aging-related case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

The interpretation remains cautious, limited, and context-dependent because the accepted evidence spans different populations, outcomes, and evidence tiers.

### Evidence Summary

The evidence base for this synthesis comprises 20 included sources. The evidence-tier distribution is: B2 (n=14), A1 (n=4), C1 (n=1), B1 (n=1). By directness, the breakdown is: indirect (n=14), direct (n=4), mechanistic (n=1), review (n=1). 12 of 20 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: adults; mice (preclinical); older adults. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

### Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

**Resolution criteria:** This thesis should be revised if larger direct human studies, prespecified endpoints, longer follow-up, or consistent cross-outcome effect directions contradict the current evidence profile.

## Limitations

**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The corpus is heavily skewed toward pharmacokinetic and short-term biomarker readouts, which means the headline clinical inferences rest on a narrow slice of the evidence space. Across the 20 curated references, the dosing-pharmacokinetic, safety-comorbidity, and contextual-other outcome classes are populated largely by trials of weeks to a few months in duration, with follow-up windows that do not extend to the time horizons needed to detect hard clinical events. No long-term mortality trial or cardiovascular outcome trial in non-diabetic older adults is represented in this corpus, so any framing of NR supplementation as broadly cardioprotective or longevity-relevant cannot be supported by the sources in hand. Mechanistic plausibility for NAD-repletion benefits therefore coexists with a near-complete absence of RCT-grade hard-endpoint confirmation, and that asymmetry is the dominant constraint on the conclusions.

Several clinically relevant outcomes in this synthesis are touched by only a single source, which makes them unreplicable within the corpus. Single-study effects cannot be cross-validated against a second independent RCT in the corpus; if the source trial had a positive-control, dosing, or enrollment idiosyncrasy, the apparent signal would not survive triangulation. Wherever a headline number depends on a lone study, the uncertainty interval is effectively wider than any reported p-value would suggest.

Population specificity further constrains external validity. The enrolled samples are predominantly middle-aged and older adults, healthy volunteers, or narrow clinical subgroups such as patients with acute kidney injury (Simic 2020 [bundle:2]), menopause transition (Holmes 2026 [bundle:8]), or subjective cognitive decline and mild cognitive impairment (Wu 2025b [bundle:7]). Children, adolescents, pregnant women, and adults with established cardiovascular disease, heart failure, or chronic kidney disease are not represented, so translating the observed NAD+-elevation signals to these groups is unsupported by the present corpus.

What the corpus does not capture is equally consequential: hard cardiovascular endpoints (myocardial infarction, stroke, heart-failure hospitalization), renal outcomes beyond the acute kidney-injury subgroup (Simic 2020 [bundle:2]), incident diabetes, and fracture or fall endpoints are absent. Even surrogate functional outcomes such as gait speed are not directly measured against canonical thresholds, so an NR-induced change cannot be benchmarked against the ~0.1 m/s substantial-improvement threshold (Perera 2006), the 0.05 m/s annual age-related decline (Bohannon 1997), or the 0.8 m/s frailty cutoff (Studenski 2011) within the present data. Similarly, grip strength is not adjudicated against the EWGSOP2 sarcopenia cutoffs of 27 kg for men and 16 kg for women (Cruz-Jentoft 2019). Without these endpoints and thresholds, the corpus can only describe biomarker movement, not functional or hard-outcome translation.

Finally, several clinically relevant claims rely on indirect or mechanistic support rather than direct RCT evidence in the target population, which is the canonical surrogate-endpoint caveat (Ioannidis 2005). Most of the contextual-other outcome class is graded indirect in the source metadata, and the most-cited mechanistic anchor (Trammell 2016 [bundle:17]) is preclinical work in mice. The Lee 2024 [bundle:10], Richard 2026 [bundle:9], and Harasim-Krawcewicz 2026 [bundle:13] entries sit in in-vitro or animal-model territory, so any inference that NR-driven NAD+ repletion will translate to clinically meaningful improvements in glioblastoma, locomotor defects, or endothelial purine metabolism is not directly supported by human RCT data in this corpus. Until mechanism-to-clinic translation is empirically demonstrated, mechanistic plausibility can be interpreted as hypothesis-generating rather than as evidence of clinical benefit. Trammell 2016 [bundle:17], Richard 2026 [bundle:9], Harasim-Krawcewicz 2026 [bundle:13] provide animal/preclinical context only.

## Conclusion

The conclusion is limited to claims that survive source qualification, source-context checks, and final audit gates.

### Bounded conclusion

This synthesis supports a bounded interpretation across 20 included sources. The evidence tiers are B2 (n=14), A1 (n=4), C1 (n=1), B1 (n=1), and directness is indirect (n=14), direct (n=4), mechanistic (n=1), review (n=1). Effect directions are unclear (n=16), null (n=4), with 12 sources carrying source-traced p-values and 64 documented cross-source tensions. These counts define the ceiling for the paper's claim strength: the conclusion can identify where the corpus is coherent, but it cannot turn indirect, heterogeneous, or mixed evidence into a clinical recommendation.

The closing inference should therefore follow the evidence map rather than the topic label. Direct human sources carry the most weight when they measure clinically proximate outcomes in the population under review. Indirect clinical sources, reviews, mechanistic papers, and protocols remain useful, but they define context, plausibility, and uncertainty rather than proof of effect. Where directions conflict, the safer conclusion is that design, endpoint, eligibility, comparator, or follow-up differences may be controlling the signal. Where findings are null or mixed, those results remain part of the answer because they limit how far a positive or mechanistic claim can travel.

The practical takeaway is bounded and revisable. The paper can be interpreted as a source-traced map of what the current source set can support, not as a treatment guideline or a pooled efficacy claim. A stronger future conclusion would require aligned direct evidence, durable endpoints, and fewer unresolved cross-source tensions. Until then, the responsible conclusion is to preserve uncertainty, state the strongest supported signal narrowly, make the remaining research gaps visible, and keep downstream reuse tied to the same source-level limits.

## What This Synthesis Adds

This synthesis maps 20 included sources on NAD+ Intervention Nicotinamide Riboside NR Effects across 6 outcome classes and 64 cross-study disagreements. It separates endpoint-specific evidence from broad clinical-translation claims so that favorable biomarker signals are not treated as proof of durable clinical benefit.

Across 20 curated reference papers, the evidence base for NAD+ shows a context-dependent profile. Null findings dominate: contextual other. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the indirectness gap between Lee 2024 [bundle:10] and Wu 2025a [bundle:3] on contextual adjacent evidence (severity 3/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Diaz-Urbina 2026 [bundle:15]) emphasize convergent signals on NAD+ Intervention Nicotinamide Riboside NR Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

### Boundary-Condition Matrix

| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |
|---|---:|---:|---|---|
| cardiometabolic | 0 | 4 | unclear | direct interventional hard-endpoint gap |
| muscle function | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| mechanism | 0 | 1 | unclear | direct interventional hard-endpoint gap |
| contextual adjacent evidence | 1 | 9 | null, unclear | replication gap |
| dosing and pharmacokinetics | 2 | 1 | unclear | replication gap |
| safety and comorbidity | 1 | 0 | unclear | replication gap |

### Evidence-Gap Priority

| Priority | Gap | Rationale |
|---|---|---|
| P1 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 4 indirect sources; direction profile: unclear |
| P2 | muscle function: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P3 | mechanism: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |
| P4 | contextual adjacent evidence: replication gap | 1 direct and 9 indirect sources; direction profile: null, unclear |
| P5 | dosing and pharmacokinetics: replication gap | 2 direct and 1 indirect sources; direction profile: unclear |

### Next-Study Design Recommendation

The next high-yield study for NAD+ Intervention Nicotinamide Riboside NR Effects should target the **cardiometabolic** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

## Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

### Load-Bearing Included Studies

- Simic 2020 [bundle:2]; tier=A1; directness=direct; endpoint=safety comorbidity; direction=unclear; representative statistic=P = 0.002.
- Airhart 2017 [bundle:18]; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P = 0.001.
- Wu 2025a [bundle:3]; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.
- Dellinger 2017 [bundle:20]; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P ≤ 0.01.
- Diaz-Urbina 2026 [bundle:15]; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear.
- Berven 2026 [bundle:1]; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P = 0.01.
- Martens 2018 [bundle:16]; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.006.
- Reyna 2026 [bundle:4]; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.01.
- Elhassan 2019 [bundle:19]; tier=B2; directness=indirect; endpoint=muscle function; direction=unclear; representative statistic=P < 0.001.
- Roy 2026 [bundle:5]; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. Dellinger 2017 [bundle:20] provides animal/preclinical context only.

### Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

- Simic 2020 [bundle:2]: outcome=safety comorbidity; directness=direct; tier=A1; direction=unclear; claims=86.
- Airhart 2017 [bundle:18]: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=unclear; claims=66.
- Wu 2025a [bundle:3]: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=unclear; claims=58.
- Dellinger 2017 [bundle:20]: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=unclear; claims=49.
- Diaz-Urbina 2026 [bundle:15]: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1.
- Berven 2026 [bundle:1]: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=unclear; claims=178.
- Martens 2018 [bundle:16]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=97.
- Reyna 2026 [bundle:4]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=57.
- Elhassan 2019 [bundle:19]: outcome=muscle function; directness=indirect; tier=B2; direction=unclear; claims=54.
- Roy 2026 [bundle:5]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=46.
- Freeberg 2022 [bundle:6]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=42.
- Wu 2025b [bundle:7]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=36.
- Holmes 2026 [bundle:8]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=19.
- Lee 2024 [bundle:10]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12.
- Richard 2026 [bundle:9]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=12.
- Friedman 2022 [bundle:11]: outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=10.
- Visalli 2026 [bundle:12]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=9.
- Harasim-Krawcewicz 2026 [bundle:13]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=5.
- Vreones 2022 [bundle:14]: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=2.
- Trammell 2016 [bundle:17]: outcome=mechanism; directness=mechanistic; tier=C1; direction=unclear; claims=82. Trammell 2016 [bundle:17], Dellinger 2017 [bundle:20], Richard 2026 [bundle:9] provide animal/preclinical context only.

### Classification Criteria

- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

### Load-Bearing Tensions

- Severity 3 indirectness gap: Lee 2024 [bundle:10] vs Wu 2025a [bundle:3]; Wu 2025a [bundle:3] (direct, A1) vs Lee 2024 [bundle:10] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wu 2025b [bundle:7] vs Wu 2025a [bundle:3]; Wu 2025a [bundle:3] (direct, A1) vs Wu 2025b [bundle:7] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wu 2025a [bundle:3] vs Richard 2026 [bundle:9]; Wu 2025a [bundle:3] (direct, A1) vs Richard 2026 [bundle:9] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wu 2025a [bundle:3] vs Reyna 2026 [bundle:4]; Wu 2025a [bundle:3] (direct, A1) vs Reyna 2026 [bundle:4] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wu 2025a [bundle:3] vs Visalli 2026 [bundle:12]; Wu 2025a [bundle:3] (direct, A1) vs Visalli 2026 [bundle:12] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wu 2025a [bundle:3] vs Harasim-Krawcewicz 2026 [bundle:13]; Wu 2025a [bundle:3] (direct, A1) vs Harasim-Krawcewicz 2026 [bundle:13] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wu 2025a [bundle:3] vs Holmes 2026 [bundle:8]; Wu 2025a [bundle:3] (direct, A1) vs Holmes 2026 [bundle:8] (indirect) on contextual other — direct vs indirect must be kept separate
- Severity 3 indirectness gap: Wu 2025a [bundle:3] vs Roy 2026 [bundle:5]; Wu 2025a [bundle:3] (direct, A1) vs Roy 2026 [bundle:5] (indirect) on contextual other — direct vs indirect must be kept separate Richard 2026 [bundle:9], Harasim-Krawcewicz 2026 [bundle:13] provide animal/preclinical context only.

## References

- **Berven 2026.** _The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation._ iScience, 2026. DOI: 10.1016/j.isci.2026.114764 PMID: 41858901.
- **Martens 2018.** _Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD + in healthy middle-aged and older adults._ Nature Communications, 2018. DOI: 10.1038/s41467-018-03421-7 PMID: 29599478.
- **Simic 2020.** _Nicotinamide riboside with pterostilbene (NRPT) increases NAD + in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI._ BMC Nephrology, 2020. DOI: 10.1186/s12882-020-02006-1 PMID: 32791973.
- **Trammell 2016.** _Nicotinamide riboside is uniquely and orally bioavailable in mice and humans._ Nature Communications, 2016. DOI: 10.1038/ncomms12948 PMID: 27721479.
- **Airhart 2017.** _An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers._ PLoS ONE, 2017. DOI: 10.1371/journal.pone.0186459 PMID: 29211728.
- **Wu 2025a.** _Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial._ eClinicalMedicine, 2025. DOI: 10.1016/j.eclinm.2025.103633 PMID: 41357333.
- **Reyna 2026.** _Intravenous infusion of nicotinamide adenine dinucleotide (NAD + ) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting._ Frontiers in Aging, 2026. DOI: 10.3389/fragi.2026.1652582 PMID: 41704678.
- **Elhassan 2019.** _Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD + Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures._ Cell Reports, 2019. DOI: 10.1016/j.celrep.2019.07.043 PMID: 31412242.
- **Dellinger 2017.** _Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD + levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study._ NPJ Aging and Mechanisms of Disease, 2017. DOI: 10.1038/s41514-017-0016-9 PMID: 29184669.
- **Roy 2026.** _A combination of ketones and NAD + precursor preserves white matter integrity in mild cognitive impairment._ Alzheimer's & Dementia : Translational Research & Clinical Interventions, 2026. DOI: 10.1002/trc2.70278 PMID: 42344884.
- **Freeberg 2022.** _Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults._ Frontiers in Cardiovascular Medicine, 2022. DOI: 10.3389/fcvm.2022.881703 PMID: 35620522.
- **Wu 2025b.** _Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment._ Alzheimer's & Dementia : Translational Research & Clinical Interventions, 2025. DOI: 10.1002/trc2.70023 PMID: 39817194.
- **Holmes 2026.** _Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial._ Frontiers in Aging, 2026. DOI: 10.3389/fragi.2026.1773667 PMID: 42211736.
- **Lee 2024.** _The compartment-specific manipulation of the NAD + /NADH ratio affects the metabolome and the function of glioblastoma._ Scientific Reports, 2024. DOI: 10.1038/s41598-024-71462-8 PMID: 39232046.
- **Richard 2026.** _NAD + and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations._ JCI Insight, 2026. DOI: 10.1172/jci.insight.181812 PMID: 41574612.
- **Friedman 2022.** _ODP205 Hepatic steatosis induced by Nicotine plus Coca Cola is prevented by Nicotinamide riboside (NR) that increases mitochondrial NAD+._ Journal of the Endocrine Society, 2022. DOI: 10.1210/jendso/bvac150.657
- **Visalli 2026.** _Mitochondrial Resilience in Glaucoma: Targeting NAD + Metabolism and Oxidative Stress in Retinal Ganglion Cell Degeneration with Nicotinamide Riboside and Berberine: Preliminary Clinical Evidence._ Diseases, 2026. DOI: 10.3390/diseases14020056 PMID: 41745094.
- **Harasim-Krawcewicz 2026.** _NAD + Enhancer Nicotinamide Riboside Alters Extracellular Purine Metabolism in Human Endothelial Cells._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27073267 PMID: 41977445.
- **Vreones 2022.** _Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin._ Aging Cell, 2022. DOI: 10.1111/acel.13754 PMID: 36515353.
- **Diaz-Urbina 2026.** _Long-term region-specific mitochondrial respiration impairment after perinatal asphyxia is prevented by the NAD⁺ donor nicotinamide riboside: A real-time organotypic metabolic profiling approach._ Pharmacol Res, 2026. DOI: 10.1016/j.phrs.2026.108190 PMID: 41985771.

{
  "article_type": "research_synthesis",
  "domain_slug": "longevity",
  "researka_object_type": "submission",
  "researka_submission_id": "5889e54b-b146-421f-8b03-7450494c52cf",
  "title": "Research Synthesis: NAD+ Intervention Nicotinamide Riboside NR Effects \u2014 full paper"
}